Kiromic BioPharma has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $2 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Kiromic BioPharma is raising $2,000,000.00 in new funding. About Kiromic BioPharma: Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
To learn more about Kiromic BioPharma, visit http://kiromic.com/
Contact:
Pietro Bersani, Chief Executive Officer
832-968-4888
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.